Evrenzo self attestation

Are you a Healthcare Professional?

This site is intended only for Healthcare Professionals, particularly those who are experienced in the management of anaemia associated with chronic kidney disease.

Information for patients

The website you have tried to access contains clinical information designed specifically for medical professionals experienced in treating this condition. If you have any questions about your health or treatment, please consult your doctor.

 

Astellas
evrenzo leavingsoon

You are leaving the website

You are now leaving an Astellas Pharma Ltd. website.
Astellas bears no responsibility for the content of any 3rd party material
nor how it might be used. Click OK to proceed.

Dialysis-dependent

  • EVRENZO was as effective as ESA in patients new to dialysis1

    Dialysis dependent table

    Patients recently started on dialysis and treated with EVRENZO achieved and maintained target Hb levels comparable with those treated with ESA1

    Dialysis Dependent 1

    DD, dialysis-dependent; ESA, erythropoiesis-stimulating agent; Hb, haemoglobin; IDD, incident dialysis-dependent; NDD, non-dialysis-dependent.

    Reference

    • EVRENZO SmPC.

  • EVRENZO reduces dependence on IV iron in patients new to dialysis1

    Dialysis dependent table

    Patients recently started on dialysis and treated with EVRENZO used less monthly IV iron than those treated with ESA1

    Dialysis Dependent 2

    Reference

    • EVRENZO SmPC.
    • Barratt et al. Adv Ther. 2021;38(10):5345-5360.

  • EVRENZO summary in DD

    Dialysis Dependent 3

    In dialysis-dependent CKD, EVRENZO can help your patients meet and maintain their Hb targets1

    • EVRENZO demonstrated non-inferiority in Hb correction and maintenance compared to ESA1

    • EVRENZO treatment resulted in reduced use of IV iron supplementation compared with treatment with ESA in patients just started dialysis1

    • Patients currently treated with an ESA can be converted to EVRENZO, however, conversion of dialysis patients otherwise stable on ESA treatment is only to be considered when there is a valid clinical reason1

    CKD, chronic kidney disease; ESA, erythropoiesis-stimulating agent; Hb, haemoglobin; IV, intravenous.

    Reference

    • EVRENZO SmPC.



EVRENZO™ (roxadustat), 20, 50, 70, 100 och 150 mg filmdragerade tabletter, B03XA05, Rx, F

▼Detta läkemedel är föremål för utökad övervakning. Detta kommer att göra det möjligt att snabbt identifiera ny säkerhetsinformation. Hälso- och sjukvårdspersonal uppmanas att rapportera varje misstänkt biverkning.

Indikationen är behandling av vuxna patienter med symtomatisk anemi associerad med kronisk njursjukdom (CKD). Kontraindikationer är överkänslighet mot den aktiva substansen, jordnötter, soja eller hjälpämne, användning under graviditetens 3e trimester samt amning. Varningar och försiktighet inkluderar risk för allvarliga kardiovaskulära och trombovaskulära händelser, krampanfall och allvarliga infektioner inklusive sepsis. Ska inte sättas in hos kvinnor som planerar att bli gravida eller under graviditet. Felanvändning kan leda till en överdrivet förhöjd hematokrit vilket kan leda till livshotande komplikationer i hjärt-kärlsystemet. 

Astellas Pharma AB, Box 21046, 200 21 Malmö. Produktresumé 2022-09.  

För ytterligare information och förpackningar se www.fass.se.